[go: up one dir, main page]

WO2016123054A3 - Kinase drug combinations and methods of use thereof - Google Patents

Kinase drug combinations and methods of use thereof Download PDF

Info

Publication number
WO2016123054A3
WO2016123054A3 PCT/US2016/014831 US2016014831W WO2016123054A3 WO 2016123054 A3 WO2016123054 A3 WO 2016123054A3 US 2016014831 W US2016014831 W US 2016014831W WO 2016123054 A3 WO2016123054 A3 WO 2016123054A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
methods
kinase
drug combinations
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/014831
Other languages
French (fr)
Other versions
WO2016123054A2 (en
Inventor
Gary L. Johnson
Lee M. GRAVES
Jian Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of WO2016123054A2 publication Critical patent/WO2016123054A2/en
Publication of WO2016123054A3 publication Critical patent/WO2016123054A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure relates to method for inhibiting cancer cell growth or inducing apoptosis in cancer cells by inhibiting kinome reprogramming in a combination therapy involving kinase inhibitors. A kinase inhibitor in combination with a P-TEFb inhibitor and/or p300/CBP inhibitor provides a stable growth suppression of the cancer cells, blocking kinome reprogramming response to kinase inhibitors.
PCT/US2016/014831 2015-01-26 2016-01-26 Kinase drug combinations and methods of use thereof Ceased WO2016123054A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562107788P 2015-01-26 2015-01-26
US62/107,788 2015-01-26
US201562144457P 2015-04-08 2015-04-08
US62/144,457 2015-04-08
US201562195435P 2015-07-22 2015-07-22
US62/195,435 2015-07-22

Publications (2)

Publication Number Publication Date
WO2016123054A2 WO2016123054A2 (en) 2016-08-04
WO2016123054A3 true WO2016123054A3 (en) 2016-10-20

Family

ID=56544522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/014831 Ceased WO2016123054A2 (en) 2015-01-26 2016-01-26 Kinase drug combinations and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2016123054A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007345526B2 (en) 2007-02-01 2013-02-28 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
KR101709492B1 (en) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
KR102662814B1 (en) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 Compositions and treatment methods for treating complement-related diseases
ES3010661T3 (en) 2016-02-26 2025-04-04 Univ Leland Stanford Junior Pi-kinase inhibitors with anti-infective activity
MX2019002121A (en) 2016-08-23 2019-08-12 Genentech Inc Combination therapy for the treatment of pancreatic cancer.
WO2018078922A1 (en) * 2016-10-24 2018-05-03 国立大学法人福井大学 Preventive agent and therapeutic agent for cataracts, and use of hat inhibitor for production thereof
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies
MX393780B (en) 2017-01-17 2025-03-24 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018170464A1 (en) * 2017-03-17 2018-09-20 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of tgfb2 expression
WO2020055698A1 (en) * 2018-09-12 2020-03-19 Denovo Biopharma Llc Combination of enzastaurin and inhibitors of btk and uses thereof
WO2020146657A1 (en) * 2019-01-11 2020-07-16 The Board Of Trustees Of The Leland Stanford Junior University Pi4-kinase inhibitors with anti-cancer activity
AU2020241869B2 (en) 2019-03-21 2025-02-13 The Board Of Trustees Of The Leland Stanford Junior University PI4-kinase inhibitors and methods of using the same
CA3153456A1 (en) 2019-10-02 2021-04-08 Stefanie Fluckiger-Mangual Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
CN111012774A (en) * 2020-03-02 2020-04-17 南通大学附属医院 Application of JQ-1 in preparation of pancreatic cancer treatment drug and verification method for inhibiting secretion of pancreatic cancer exosomes
CA3184076A1 (en) * 2020-06-25 2021-12-30 Stefanie Fluckiger-Mangual Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
WO2021260109A1 (en) * 2020-06-25 2021-12-30 Tolremo Therapeutics Ag A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC
CN113318105B (en) * 2021-05-31 2023-02-03 新乡医学院 Medicinal composition containing Binimetinib for treating colon cancer and application thereof
EP4376839A4 (en) * 2021-07-26 2025-10-15 Vincerx Pharma Inc SELECTIVE CDK9 INHIBITOR FOR THE TREATMENT OF RAS-MUTANT CANCER
CN113521035B (en) * 2021-08-05 2023-04-25 河南大学 Preparation method and application of nano-medicine for combined chemoimmunotherapy
WO2025072961A1 (en) * 2023-09-29 2025-04-03 Leapfrog Bio, Inc. P110 inhibitors for the treatment of cancer
CN118593509A (en) * 2024-06-21 2024-09-06 福建医科大学附属第一医院 Use of filgotinib as a sensitizer for the anti-triple-negative breast cancer drug BBDI

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215793A1 (en) * 2005-05-13 2009-08-27 Novartis Ag Methods for treating drug resistant cancer
US20100168228A1 (en) * 2006-10-13 2010-07-01 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
WO2012138739A2 (en) * 2011-04-06 2012-10-11 Chemo-Enhanced Llc Compositions and methods for treating cancer
WO2013026890A1 (en) * 2011-08-22 2013-02-28 Lead Discovery Center Gmbh Susceptibility to selective cdk9 inhibitors
WO2013148114A1 (en) * 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215793A1 (en) * 2005-05-13 2009-08-27 Novartis Ag Methods for treating drug resistant cancer
US20100168228A1 (en) * 2006-10-13 2010-07-01 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
WO2012138739A2 (en) * 2011-04-06 2012-10-11 Chemo-Enhanced Llc Compositions and methods for treating cancer
WO2013026890A1 (en) * 2011-08-22 2013-02-28 Lead Discovery Center Gmbh Susceptibility to selective cdk9 inhibitors
WO2013148114A1 (en) * 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use

Also Published As

Publication number Publication date
WO2016123054A2 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
WO2016123054A3 (en) Kinase drug combinations and methods of use thereof
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
PH12017501155B1 (en) Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors
AU2013323736A8 (en) Multiple kinase pathway inhibitors
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MX339937B (en) Compounds and compositions as c-kit kinase inhibitors.
MX2019001125A (en) Macrocycle kinase inhibitors.
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
HK1245247A1 (en) Inhibitors of bromodomains
MD20170016A2 (en) Aminopyrimidinyl compounds as JAK inhibitors
HK1245677A1 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
PH12016500330A1 (en) Certain chemical entities, compositions, and methods
SG10201902074UA (en) Heterocyclic compounds and uses thereof
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MY169987A (en) Selective pi3k delta inhibitors
CA2983481A1 (en) Janus kinase inhibitor
MX2014002486A (en) Compounds and compositions as pdgfr kinase inhibitors.
PH12015502698A1 (en) Dual selective pi3 delta and gamma kinase inhibitors
HK1221144A1 (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
EP3390364A4 (en) Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors
WO2014038881A3 (en) Protein kinase inhibitor comprising pyridine derivatives
HK40015050A (en) Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16743930

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16743930

Country of ref document: EP

Kind code of ref document: A2